Melike Demir1, Halide Kaya2, Mahsuk Taylan2, Aysun Ekinci3, Sureyya Yılmaz2, Fatma Teke4, Cengizhan Sezgi2, Abdullah Cetin Tanrikulu2, Fatih Meteroglu5, Abdurrahman Senyigit2. 1. Department of Chest Disease, Dicle University Faculty of Medicine, Sur, 21280, Diyarbakir, Turkey. melikedoktor@hotmail.com. 2. Department of Chest Disease, Dicle University Faculty of Medicine, Sur, 21280, Diyarbakir, Turkey. 3. Department of Biochemistry, Dicle University Faculty of Medicine, 21280, Diyarbakir, Turkey. 4. Department of Radiation Oncology, Dicle University Faculty of Medicine, 21280, Diyarbakir, Turkey. 5. Department of Thoracic Surgery, Dicle University Faculty of Medicine, 21280, Diyarbakir, Turkey.
Abstract
INTRODUCTION: The purpose of this study was to investigate the potential value of certain biomarkers in predicting the presence of malignant pleural mesothelioma (MPM) in individuals environmentally exposed to asbestos. METHODS: This prospective study investigated three groups; a control group composed of 41 healthy subjects, an asbestos exposure group consisting of 48 individuals, and a MPM group consisting of 42 patients. Serum levels of soluble mesothelin-related peptide (SMRP), thioredoxin-1 (TRX), epidermal growth factor receptor (EGFR), fibulin-3, syndecan-1 (SDC-1), and mesothelin were determined. RESULTS: Benign pleural plaques were present in 27 (58.3 %) of the individuals in the asbestos exposure group. The asbestos exposure group had significantly higher mean TRX, SMRP, and mesothelin levels compared to the control group (p = 0.023, p = 0.011, and p < 0.001, respectively). Compared to the asbestos exposure group, the MPM group had significantly higher mean EGFR, TRX, SMRP, and fibulin-3 levels (p = 0.041, p = 0.023, p = 0.002, and p = 0.001, respectively), and significantly lower mean SDC-1 levels (p = 0.002). Unlike the other biomarkers, SMRP and TRX levels increased in a graded fashion among the control, asbestos exposure, and MPM groups, respectively. Area under the curve values for SMRP and TRX were 0.86 and 0.72, respectively (95 % CI 0.79-0.92 and p < 0.001 for SMRP, and 95 % CI 0.62-0.81 and p < 0.001 for TRX). The cut-off value for SMRP was 0.62 nmol/l (sensitivity: 97.6 %, specificity: 68.9 %, positive predictive value (PPV): 56.2 %, and negative predictive value (NPV): 98.3 %) and for TRX was 156.67 ng/ml (sensitivity: 92.9 %, specificity: 77.6 %, PPV: 41.4 %, and NPV: 92.1 %). The combination of the biomarkers reached a sensitivity of 100 %, but had lower specificity (as high as 27.7 %). CONCLUSIONS: Serum biomarkers may be helpful for early diagnosis of MPM in asbestos-exposed cases. SMRP and TRX increased in a graded fashion from the controls to asbestos exposure and MPM groups. These two seem to be the most valuable biomarkers for the diagnosis of MPM, both individually and in combination.
INTRODUCTION: The purpose of this study was to investigate the potential value of certain biomarkers in predicting the presence of malignant pleural mesothelioma (MPM) in individuals environmentally exposed to asbestos. METHODS: This prospective study investigated three groups; a control group composed of 41 healthy subjects, an asbestos exposure group consisting of 48 individuals, and a MPM group consisting of 42 patients. Serum levels of soluble mesothelin-related peptide (SMRP), thioredoxin-1 (TRX), epidermal growth factor receptor (EGFR), fibulin-3, syndecan-1 (SDC-1), and mesothelin were determined. RESULTS:Benign pleural plaques were present in 27 (58.3 %) of the individuals in the asbestos exposure group. The asbestos exposure group had significantly higher mean TRX, SMRP, and mesothelin levels compared to the control group (p = 0.023, p = 0.011, and p < 0.001, respectively). Compared to the asbestos exposure group, the MPM group had significantly higher mean EGFR, TRX, SMRP, and fibulin-3 levels (p = 0.041, p = 0.023, p = 0.002, and p = 0.001, respectively), and significantly lower mean SDC-1 levels (p = 0.002). Unlike the other biomarkers, SMRP and TRX levels increased in a graded fashion among the control, asbestos exposure, and MPM groups, respectively. Area under the curve values for SMRP and TRX were 0.86 and 0.72, respectively (95 % CI 0.79-0.92 and p < 0.001 for SMRP, and 95 % CI 0.62-0.81 and p < 0.001 for TRX). The cut-off value for SMRP was 0.62 nmol/l (sensitivity: 97.6 %, specificity: 68.9 %, positive predictive value (PPV): 56.2 %, and negative predictive value (NPV): 98.3 %) and for TRX was 156.67 ng/ml (sensitivity: 92.9 %, specificity: 77.6 %, PPV: 41.4 %, and NPV: 92.1 %). The combination of the biomarkers reached a sensitivity of 100 %, but had lower specificity (as high as 27.7 %). CONCLUSIONS: Serum biomarkers may be helpful for early diagnosis of MPM in asbestos-exposed cases. SMRP and TRX increased in a graded fashion from the controls to asbestos exposure and MPM groups. These two seem to be the most valuable biomarkers for the diagnosis of MPM, both individually and in combination.
Authors: Geneva M Cunningham; Madeline G Roman; Lisa C Flores; Gene B Hubbard; Adam B Salmon; Yiqiang Zhang; Jonathan Gelfond; Yuji Ikeno Journal: Arch Biochem Biophys Date: 2015-02-26 Impact factor: 4.013
Authors: Mehmet Bayram; Isa Dongel; Ali Akbaş; Ismail Benli; Muhammed Emin Akkoyunlu; Nur Dilek Bakan Journal: Lung Date: 2013-10-30 Impact factor: 2.584
Authors: Victor L Roggli; Anupama Sharma; Kelly J Butnor; Thomas Sporn; Robin T Vollmer Journal: Ultrastruct Pathol Date: 2002 Mar-Apr Impact factor: 1.094
Authors: Lisa Brusselmans; Lieselot Arnouts; Charissa Millevert; Joyce Vandersnickt; Jan P van Meerbeeck; Kevin Lamote Journal: Transl Lung Cancer Res Date: 2018-10
Authors: Georg Johnen; Katarzyna Gawrych; Irina Raiko; Swaantje Casjens; Beate Pesch; Daniel G Weber; Dirk Taeger; Martin Lehnert; Jens Kollmeier; Torsten Bauer; Arthur W Musk; Bruce W S Robinson; Thomas Brüning; Jenette Creaney Journal: BMC Cancer Date: 2017-05-30 Impact factor: 4.430